Dermata Therapeutics (DRMAW) Stock Analysis

What Dermata Therapeutics does

Dermata Therapeutics, Inc., a biotechnology company in the clinical development stage, is headquartered in San Diego, California, and was established in 2014. The firm's core mission is to develop innovative treatments for a variety of dermatological and cosmetic skin conditions. Its flagship investigational product, DMT310, is a topical formula applied once weekly that is currently undergoing clinical trials. This primary compound is being evaluated for its effectiveness against acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. Additionally, the company is advancing DMT410, which is intended to address hyperhidrosis (excessive sweating) and other aesthetic concerns.

Key metrics

ETFs linked to DRMAW

Broad-market and Healthcare sector ETFs an investor holding Dermata Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how DRMAW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Dermata Therapeutics?

Dermata Therapeutics trades under the ticker DRMAW on NASDAQ.

Which exchange is DRMAW listed on?

DRMAW is listed on NASDAQ.

What sector does Dermata Therapeutics operate in?

Dermata Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze DRMAW in a portfolio?

PortView shows DRMAW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.